Business
AngioDynamics Completes Enrollment for PRESERVE Clinical Study
Pivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics,
About this update from Angiodynamics, Inc.
[{"type":"text","content":"\nPivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population\n\n\n LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced the completion of enrollment and final treatment in its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE).\n\n\nThe PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).\n\n\n\"The PRESERVE study demonstrates AngioDynamics’ commitment to innovating care delivery,” said Juan Carlos Serna, AngioDynamics Senior Vice President of Clinical and Scientific Affairs. “As we mark the completion of enrollment and final treatment in the study, we take another important step towards demonstrating the NanoKnife System’s ability to expand treatment options for patients with intermediate-risk prostate cancer and advance our mission to improve patient quality of life. We appreciate the support provided by our PRESERVE study sites and the partnership with the SUO-CTC team in this important effort.”\n\n\nFinal patient enrollment in the study was initially announced during AngioDynamics’ Fiscal 2023 Fourth Quarter and Full-Year Financial Results conference call on July 12, 2023.\n\n\nCo-Principal Investigators leading the study are Jonathan Coleman, MD, Urologic Surgeon, Memorial Sloan Kettering Cancer Center, and Arvin George, MD, Urologic Surgeon, University of Michigan. The PRESERVE study will have its primary endpoint analysis at 12 months following treatment.\n\n\n“As diagnostic tools develop to allow earlier identification and localization of clinically significant forms of prostate cancer, there is a matching need to establish effective forms of treatment that target the disease and preserve patients' quality of life. Evidence is growing to support the use of partial gland ablation for prostate cancer as a reasonable alternative treatment strategy in carefully selected patients. The PRESERVE study, studying the efficacy of irreversible electroporation (IRE) with the NanoKnife Syste...